Key facts
- It has raised $37.3M across 1 recorded rounds; the latest was Early Stage VC ($16.4M) in Jan 2026.
- Notable investors include Louisiana Economic Development, 2b AHEAD Ventures, ARC Innovation Center, BRF(Shreveport), BVM Capital — 8 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Starget Pharma
Funding rounds
1 roundsAbout Starget Pharma
Operator of a biotechnology company intended to specialize in the diagnosis and targeted treatment of cancer using targeted radioactive radiation. The company's research is in the development of molecules that serve as a vector for the targeted transfer of radioactive isotopes to cancerous tumors, where there is an unmet medical need, enabling doctors and medical practitioners to provide effective treatment for cancer.
- Sector
- Healthcare
- HQ
- Ramat HaSharon, Israel
- Founded
- 2019
- Employees
- 18
- Website
- stargetpharma.com/
- Ownership
- Privately Held (backing)
Starget Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Starget Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Starget Pharma in its N-PORT filings yet. We sweep new filings monthly.